What is Osteogenics Biomedical?
Founded in 1996, Osteogenics Biomedical operates as a specialized medical manufacturing entity focused on the development and distribution of advanced bone grafting products. The company's portfolio is extensive, encompassing mineralized allografts, xenografts, PTFE and collagen membranes, synthetic putty, and precision fixation systems. By integrating high-quality manufacturing standards with a deep understanding of dental and medical applications, the firm has established itself as a critical supplier for practitioners requiring reliable regenerative materials. Their operational model, which includes dedicated warehouse facilities, allows for efficient supply chain management, supporting both business-to-business and consumer-facing market segments.
How much funding has Osteogenics Biomedical raised?
Osteogenics Biomedical has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Osteogenics Biomedical
PPP
Public-Private Partnership
What's next for Osteogenics Biomedical?
With the recent strategic investment, Osteogenics Biomedical is poised to optimize its manufacturing infrastructure and potentially broaden its product pipeline. The focus will likely shift toward scaling the production of its proprietary dental sutures and synthetic putty, while simultaneously strengthening its North American distribution channels. As the company matures, the emphasis on clinical efficacy and product innovation will remain central to its growth strategy. By leveraging this capital, the firm aims to reinforce its competitive advantage, ensuring that its technological advancements in bone grafting continue to meet the evolving demands of the global healthcare market.
See full Osteogenics Biomedical company page
